Cancer Biomarkers Market by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022

  • ID: 4033348
  • Report
  • Region: Global
  • 172 pages
  • Allied Analytics LLP
1 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd.
  • Genomic Health, Inc.
  • GlaxoSmithKline plc
  • MORE
Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, and Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Other Cancers), Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Cancer biomarkers are biomolecules that specifies the existence of cancer or cancerous cells in the body. These are generally molecules that are released due to the presence of a tumor or a particular indication in the body to the presence of cancer. These molecules are densely distributed in tissues, urine, serum, blood, and other body fluids. Their expression levels serve as the basis or indication of any abnormal process or a disease.

The market size of the global cancer biomarkers market was valued at $6,521 million in 2015 and is estimated to grow at a CAGR of 13% over the forecast period to reach $15,737 million in 2022. Market growth is attributed to the increasing incidences of cancers such as lung cancer, breast cancer, and prostate cancer among others coupled with growing importance of biological and targeted drug therapies and technological advancements in the field of cancer treatment. However, unregulated government laws and reimbursement policies; as well as high cost of drug development and threat of failure are anticipated to have an adverse effect on the market growth. Nevertheless, advancement in cancer drugs research and significant unmet need in cancer diagnosis are estimated to overshadow these restraints.

The global cancer biomarkers market is segmented based on profiling technology, biomolecules, cancer type, application, and geography. By profiling technology, the market is segmented into omic technologies, imaging technologies, immunoassays and cytogenetics based tests. Based on biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glycoprotein biomarkers. Amongst these, genetic biomarkers are widely used in the market owing to better diagnostic and therapeutic usage as compared to protein and glycoprotein biomarkers.

The various cancer types include breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Amongst these, lung cancer is the major cancer type where biomarkers are being used for detection. Owing to high tobacco consumption and smoking, lung cancer has increased at an alarming rate. CEACAM-5/CD66e, Cytokeratin 19, EGF R/ErbB1, Enolase 2/Neuron-specific Enolase, Lactate Dehydrogenase A/LDHA, Lactate Dehydrogenase B/LDHB, Napsin A and PDGFRL are some of the major cancer biomarkers used for lung cancer detection.

Geographically, North America is the leading revenue generating region, due to high incidence rate of cancer, growth in awareness towards cancer and higher cancer biomarker testing. Asia-Pacific is growing at the fastest CAGR due to rise in awareness, increased disposable income, and affordability for advanced cancer treatments.

Companies have adopted collaboration and partnership as their key development strategies. Increase in focus on collaboration and partnership is mainly for the development of innovative technologies in the field of cancer biomarkers. In May 2016, Roche received an approval by FDA for its first anti-PD-L1 cancer immunotherapy namely Tecentriq (atezolizumab), thereby expanding its product portfolio.

KEY BENEFITS FOR STAKEHOLDERS:

The drivers, restraints, and opportunities in the global cancer biomarkers market are expected to help in understanding the market behavior better.
The market estimations are a result of high-end analysis of the key market segments for the period of 2014–2022
Projections in the report are made by analyzing the current market trends and future market potential for the forecast period in terms of value. The analysis helps in understanding the strategies adopted by various companies for the growth of the global cancer biomarkers market.
Country level analysis has been done to provide micro market sizing of cancer biomarkers in different regions
Porter's five forces model gives an in-depth analysis of bargaining power of buyers and suppliers, threats of new entrants & substitutes, and competition amongst the key market players.

KEY MARKET SEGMENTS:

By Profiling Technology

Omic Technologies
Imaging Technologies
Immunoassays
Cytogenetics Based Tests

By Biomolecules

Genetic Biomarkers
Protein Biomarkers
Glycoprotein Biomarkers

By Cancer Type

Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Other Cancers

By Application

Diagnostics
Drug Discovery and Development
Prognostics
Risk Assessment
Others

BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Russia
Rest of Europe
Asia-Pacific
Japan
India
China
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
UAE
Rest of LAMEA
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd.
  • Genomic Health, Inc.
  • GlaxoSmithKline plc
  • MORE
CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Biomarker diagnosis vs. conventional diagnosis
3.3 Key findings

3.3.1 Drivers

3.3.1.1 Rise in incidence and prevalence of various cancer types
3.3.1.2 Growth in importance of biological and targeted drug therapies
3.3.1.3 Expiration of key patents and biosimilars impact
3.3.1.4 Increase in acquisitions and collaborations
3.3.1.5 Technological advancements
3.3.1.6 Accuracy and reliability
3.3.1.7 Rise in investment from government, public, and private sectors
3.3.1.8 Increase in clinical trials
3.3.1.9 Growth in popularity of personalized medicine and companion diagnostics

3.3.2 Restraints

3.3.2.1 High cost of drug development and threat of failure
3.3.2.2 Unregulated government regulation and reimbursement policies
3.3.2.3 Adverse effects of cancer drug therapy

3.3.3 Opportunities

3.3.3.1 Advancement of cancer drugs research
3.3.3.2 Increased focus towards advanced treatment protocols
3.3.3.3 Significant unmet need in cancer diagnosis
3.3.3.4 Increased awareness to reduce healthcare costs
3.3.3.5 Opportunities in emerging economies

3.3.4 Top investment pockets
3.3.5 Top winning strategies

3.4 Porters five forces analysis

3.4.1 High bargaining power of suppliers
3.4.2 Low bargaining power of buyers
3.4.3 High threat from substitutes
3.4.4 Low threat of new entrants
3.4.5 High intensity of competitive rivalry

3.5 Top player positioning, 2015
3.6 Patent analysis

3.6.1 U.S. patent analysis by market participant
3.6.2 Europe patent analysis by market participant
3.6.3 China patent analysis by market participant
3.6.4 Canada patent analysis by market participant
3.6.5 Japan patent analysis by market participant
3.6.6 Other countries patent analysis by market participant

3.7 Clinical trials

CHAPTER 4 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022

4.1 Overview

4.1.1 Market size and forecast

4.1 Omic technologies

4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast
4.1.4 Genomics

4.1.4.1 Market size and forecast
4.1.4.2 Next-generation sequencing (NGS)
4.1.4.3 Microarray
4.1.4.4 Polymerase chain reaction (PCR)

4.1.5 Proteomics

4.1.5.1 Market size and forecast
4.1.5.2 Mass spectrometry
4.1.5.3D gel electrophoresis
4.1.5.4 Protein microarray technology
4.1.5.5 Antibody array technology
4.1.5.6 Peptide array technology

4.1.6 Other omic technologies

4.1.6.1 Market size and forecast
4.1.6.2 Metabolomics
4.1.6.3 Glycomics

4.2 Imaging technologies

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Magnetic resonance imaging
4.2.5 Positron emission tomography
4.2.6 Computed tomography
4.2.7 Mammography
4.2.8 Ultrasound

4.3 Immunoassays

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 Immunohistochemistry tests
4.3.5 Enzyme-linked immunosorbent assay
4.3.6 Flow cytometry

4.4 Cytogenetics-based tests

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 In situ hybridization
4.4.5 Others (karyotyping, amplichip, and in vitro diagnostic multivariate index assays [IVDMIA])

CHAPTER 5 GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE (2014-2022)

5.1 Overview

5.1.1 Market size and forecast

5.2 Genetic biomarkers

5.2.1 Market size and forecast

5.3 Protein biomarkers

5.3.1 Market size and forecast

5.4 Glyco-biomarkers

5.4.1 Market size and forecast

CHAPTER 6 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022

6.1 Overview
6.1.1 Market size and forecast
6.2 Lung cancer
6.2.1 Market size and forecast
6.3 Breast cancer
6.3.1 Market size and forecast
6.4 Colorectal cancer
6.4.1 Market size and forecast
6.5 Prostate cancer
6.5.1 Market size and forecast
6.1 Stomach cancer
6.1.1 Market size and forecast
6.2 Others
6.2.1 Market size and forecast

CHAPTER 7 CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022

7.1 Overview
7.1.1 Market size and forecast
7.2 Diagnostics
7.2.1 Market size and forecast
7.3 Drug discovery and development
7.3.1 Market size and forecast
7.4 Prognostics
7.4.1 Market size and forecast
7.5 Risk assessment
7.5.1 Market size and forecast
7.6 Others (personalized medicine, surrogate endpoints, recurrence, and therapeutics)
7.6.1 Market size and forecast

CHAPTER 8 CANCER BIOMARKERS MARKET BY GEOGRAPHY, 2014-2022

8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key market trends
8.2.2 Growth factors and opportunities
8.2.3 Market size and forecast
8.2.3.1 U.S.: market size and forecast
8.2.3.2 Canada: market size and forecast
8.2.3.3 Mexico: market size and forecast

8.3 Europe
8.3.1 Key market trends
8.3.2 Growth factors and opportunities
8.3.3 Market size and forecast
8.3.3.1 Germany: market size and forecast
8.3.3.2 UK: market size and forecast
8.3.3.3 France: market size and forecast
8.3.3.4 Italy: market size and forecast
8.3.3.5 Russia: market size and forecast
8.3.3.6 Rest of Europe: market size and forecast
8.4 Asia-Pacific
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast
8.4.3.1 Japan: market size and forecast
8.4.3.2 China: market size and forecast
8.4.3.3 India: market size and forecast
8.4.3.4 Australia: market size and forecast
8.4.3.5 Rest of Asia-Pacific: market size and forecast
8.5 LAMEA (Latin America, Middle East, and Africa)
8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.2.1 Brazil: market size and forecast
8.5.2.2 Saudi Arabia: market size and forecast
8.5.2.3 UAE: market size and forecast
8.5.2.4 Rest of LAMEA: market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 F. Hoffmann-La Roche Ltd.
9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and developments
9.2 Abbott Laboratories
9.2.1 Company overview
9.2.2 Company Snapshot
9.2.3 Operating business segments
9.2.4 Business performance
9.2.5 Key strategies & developments
9.3 GlaxoSmithKline plc
9.3.1 Company overview
9.3.2 Operating business segments
9.3.3 Business performance
9.3.4 Key strategies and developments
9.4 Novartis AG
9.4.1 Company overview
9.4.2 Operating business segments
9.4.3 Business performance
9.4.4 Key strategies and developments
9.5 Merck & Co., Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Business performance
9.5.5 Key strategies and developments
9.6 Bristol-Myers Squibb
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Business performance
9.6.4 Key strategies and developments

9.7 Eli Lilly and Company

9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Business performance
9.7.5 Key strategies and developments

9.8 Pfizer, Inc.

9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Business performance
9.8.5 Key strategies and developments

9.9 Qiagen N.V.

9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Key strategy move and development

9.10 Genomic Health, Inc.

9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Business performance
9.10.4 Key strategies and developments
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd.
  • Genomic Health, Inc.
  • GlaxoSmithKline plc
  • MORE
Cancer Biomarkers Market Report, forecasts that the global market is projected to reach $15,737 million by 2022 from $6,521 in 2015, growing at a CAGR of 13% from 2016 to 2022. Omic technologies segment accounted for more than half of the revenue share in 2015 and is expected to maintain its dominance during the forecast period. Europe and Asia-Pacific together accounted for more than half of the market share in 2015.

The market for cancer biomarkers is primarily driven by rise in prevalence of cancer cases, growing importance of biological & targeted drug therapies, technological advancements, and accuracy & reliability of cancer biomarkers for cancer detection. Moreover, rise in investments from government, public & private sector for biomarker research and technological advancements for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure, and unregulated government regulations & reimbursement policies could restrain the market. Yet, the impact of these limitations is anticipated to reduce due to substantial surge in cancer diagnosis as well as increased focus towards advanced treatment protocols.

In terms of applications, diagnostics accounted for major share of the global cancer biomarkers market in 2015, and is projected to maintain this trend throughout the forecast period growing at a CAGR of 14%.

In terms of profiling technology, omic technology is the most popular and conventional method for biomarker detection and is projected to grow at a CAGR of 12%. However, immunoassays segment is anticipated to experience higher adoption rate, majorly due to the increase in use of flow cytometry, and is expected to grow at a CAGR of 18% during the forecast period.

In the year 2015, genetic biomarkers accounted for highest revenue share and is expected to grow at a CAGR of 13% during the forecast period. The use of genetic biomarkers for detecting gene mutations and gene expressions is expected to drive the growth of the biomolecule. However, use of glyco biomarkers due to better identification of cancerous gene is further expected to increase the segment growth which is expected to grow by 14% during the forecast period.

Key Findings of the Cancer Biomarkers Market:

Immunoassays are projected to be the fastest growing segment, growing at a CAGR of 18% during the forecast period.
Omic technologies is anticipated to be the highest revenue generating segment followed by imaging technologies during 20162022.
In the year 2015, genetic biomarkers was the leading segment and is projected to grow at a CAGR of 13%.
Use of protein biomarkers was highest in North America, covering approximately 37% of the global market share in 2015.
Europe accounted for approximately one-third of the global cancer biomarkers market in 2015.
Asia-Pacific is estimated to be the fastest growing region in cancer biomarkers market, growing at a CAGR of 14%.
Mexico is projected to be the fastest growing country in the North America region growing at a CAGR of 13% during the forecast period.
China and Japan were the leading markets for cancer biomarkers in the Asia-Pacific region covering three-fifth of the total market in 2015.
North America dominated the global cancer biomarkers market. This is primarily attributed to the biomarker discoveries resulting from technological advancements. Moreover, rise in awareness about cancer as well as availability of better treatment facilities has also fueled the market growth. Europe and Asia-Pacific together accounted for around half of the market in 2015.

The companies adopted collaboration and partnership as their prime strategy to keep pace with the changing demands of consumers and strengthen their market position. The key players for this market include F.Hoffmann-La Roche Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Inc., Qiagen N.V. and Genomic Health, Inc.
Note: Product cover images may vary from those shown
5 of 6
  • F.Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Qiagen N.V.
  • Genomic Health, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll